Nishant focuses on corporate law matters. Prior to rejoining the firm, he was a legal intern in the Civil Rights Division at the Office of the Attorney General in Massachusetts. Nishant was a Summer Associate at the firm in 2013 and 2014, where he assisted attorneys in the Corporate & Securities Practice with a securities offering as well as worked with attorneys on a bankruptcy law matter.
While at law school, Nishant was the research editor for the Uniform Commercial Code Reporter-Digest and an executive board member of the AHANAS Diversity Retreat Committee.
As an undergrad, Nishant served as an executive compensation intern at Pearl Meyer and Partners and interned at the Office of the Queens County District Attorney in New York.
Experience
- Represented Aspen Aerogels, Inc. in its $275M public offering underwritten by Cowen and Company, LLC and Barclays Capital Inc.
- Represented Convertible Note PIPE with affiliate of Koch Strategic Platforms, LLC.
- Represented Koch Strategic Platforms ("KSP"), a subsidiary of Koch Investments Group, in its agreement to make a $150 million investment in Aspen through the purchase of convertible notes and common stock to support the Company's aerogel thermal barrier growth opportunities.
- Represented the underwriters in the $75M public offering of Fulcrum Therapeutics underwritten by Goldman Sachs & Co.
- Represented Sera Prognostics in its $80M initial public offering underwritten by Citi, Cowen and William Blair.
- Represented the underwriters in the $190M initial public offering of Praxis Precision Medicines, Inc. underwritten by Cowen, Evercore ISI, Piper Sandler, Wedbush PacGrow and Blackstone Capital Markets.
News & Press
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Twenty-nine Mintz Attorneys Named to 2023 New York Metro Super Lawyers List
September 22, 2023
NEW YORK – Mintz is pleased to announce that 18 attorneys have been named New York Metro Super Lawyers and 11 attorneys have been named New York Metro Rising Stars by Super Lawyers for 2023.
Mintz represented G1 Therapeutics, Inc. in its initial public offering of 7,781,564 shares of common stock. G1 Therapeutics is a clinical-stage biopharmaceutical company.
Mintz Represents Seventh Generation, Inc. in Sale to Unilever
October 27, 2016
Mintz attorneys represented Seventh Generation, Inc. in its recent sale to Unilever. Based in Vermont, Seventh Generation is a pioneer in corporate responsibility and sustainable product innovations, including plant-based detergents and household cleaners.
Recognition & Awards
- New York Super Lawyers Rising Stars: Corporate (2023)
Recent Insights
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
NEW YORK – Mintz is pleased to announce that 18 attorneys have been named New York Metro Super Lawyers and 11 attorneys have been named New York Metro Rising Stars by Super Lawyers for 2023.
